{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:28:04Z","timestamp":1786519684899,"version":"build-2736575974"},"reference-count":5,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Eosinophilic otitis media (EOM) is a rare, treatment-resistant middle ear condition characterised by eosinophilic secretions and a risk of irreversible hearing loss. The condition is often seen in patients with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and is driven by type-2 inflammation. We describe two patients in this case with severe EOM and concomitant asthma and CRSwNP, in whom conventional treatment had limited efficacy. Treatment with the IL-5 inhibitor mepolizumab resulted in marked improvement in ear symptoms, improved hearing, and reduced need for systemic steroids.<\/jats:p>","DOI":"10.61409\/v12251053","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:03:20Z","timestamp":1780038200000},"page":"1-3","source":"Crossref","is-referenced-by-count":0,"title":["Eosinophilic otitis media"],"prefix":"10.61409","author":[{"given":"Anne-Sophie","family":"Hom\u00f8e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Aan\u00e6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Tidemandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon G.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kamimura S, Ishitani K, Morozumi R, et al. Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis. Braz J Otorhinolaryngol. 2025;91(2):101555 https:\/\/doi.org\/10.1016\/j.bjorl.2024.101555","DOI":"10.1016\/j.bjorl.2024.101555"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Iino Y. Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx. 2023;50(4):479-489 https:\/\/doi.org\/10.1016\/j.anl.2022.11.004","DOI":"10.1016\/j.anl.2022.11.004"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Parietti-Winkler C, Jankowski R. Is there an association between otitis media and nasal polyposis? Curr Allergy Asthma Rep. 2011;11(6):521-525 https:\/\/doi.org\/10.1007\/s11882-011-0229-0","DOI":"10.1007\/s11882-011-0229-0"},{"key":"ref3","unstructured":"Lazzeroni M, Elzinga H, Merkus P, et al. Management of eosinophilic otitis media in the era of biological therapy: systematic review and proportion meta-analysis. Rhinology. 2025;63(2):145-152"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Suikkila A, Lyly A, Saarinen R, et al. Biologic therapy relieves otologic symptoms and signs in patients with asthma and chronic rhinosinusitis with nasal polyps. Laryngoscope Investig Otolaryngol. 2025;10(4):e70212. https:\/\/doi.org\/10.1002\/lio2.70212","DOI":"10.1002\/lio2.70212"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:34:43Z","timestamp":1786516483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12251053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":5,"URL":"https:\/\/doi.org\/10.61409\/v12251053","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}